Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine che...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Clin Oncol
Hlavní autoři: Suto, Takeshi, Ishiguro, Megumi, Hamada, Chikuma, Kunieda, Katsuyuki, Masuko, Hiroyuki, Kondo, Ken, Ishida, Hideyuki, Nishimura, Genichi, Sasaki, Kazuaki, Morita, Takayuki, Hazama, Shoichi, Maeda, Koutarou, Mishima, Hideyuki, Ike, Hideyuki, Sadahiro, Sotaro, Sugihara, Kenichi, Okajima, Masazumi, Saji, Shigetoyo, Sakamoto, Junichi, Tomita, Naohiro
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Japan 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486458/
https://ncbi.nlm.nih.gov/pubmed/28078540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-016-1083-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky